gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CORTHealthcarePharmaceuticals

Corcept Therapeutics Inc. (CORT)

$79.22−3.31%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$77.44▲ 4.42% in range
Nov 3, 2025Low $32.15 · High $123.57Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Corcept Therapeutics closed at $79.22 on Nov 4, down 3.31%, 35.9% below its 52-week closing high. Volume of 2.2M shares was 2.20× its 20-day average (well above normal).

Split-adjusted performance: -33.7% over one month, +51.9% over six months, +6.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $256.15M, up 31.7% from a year earlier, with a net margin of 16.8%.

Short interest was 8.6M shares at the Oct 15 settlement (9.0% of float, 12.3 days to cover).

Market cap$8.56B108.1M shares
Revenue · quarter$256.1M+31.7% YoY
Diluted EPS$0.36+24.1% YoY
P/E · TTM157.2×P/S 10.3×
Net margin16.8%Gross 98.4%
Dividend yieldNone
52-week range32.15 – 123.57−35.9% from high
Volume2.2M2.20× 20-day avg
Volatility · 60d59.5%Annualised
Short % of float9.0%12.3 days to cover
Net cash$308.2MCash $308.2M
Next earnings—Not scheduled
Split-adjusted performance
1W −8.2%1M −33.7%3M −26.6%6M +51.9%YTD +127.6%1Y +6.8%3Y +189.9%5Y +350.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum93
Revenue growth71
Net margin84
Value (low P/E)0
Size93

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short8.6M+0.6% vs prior
Days to cover12.3Settled Oct 15
% of float9.0%
Short vol. 10d50.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CORTCorcept Therapeutics$79.22−3.31%+51.9%+31.7%16.8%157.2$8.56B
ARWRArrowhead Research$61.65+3.56%−22.1%+171.0%−258.2%—$8.71BCompare
CYTKCytokinetics$63.60+2.07%−15.0%−57.1%−694.4%—$8.84BCompare
PRAXPraxis Precision Medicines$284.79+1.53%−15.8%———$7.95BCompare
MDGLMadrigal Pharmaceuticals$400.43+1.04%−25.8%+50.1%12.9%—$9.25BCompare
SYRESpyre Therapeutics$99.04−0.23%+35.7%———$9.26BCompare
PTGXProtagonist Therapeutics$143.37+2.23%+37.9%+3749.2%76.3%111.9$9.28BCompare
TGTXTG Therapeutics$61.63+1.45%+46.8%+70.3%3.2%21.4$9.43BCompare
ALKSAlkermes$45.89+0.44%+29.9%+21.8%3.4%—$7.70BCompare

News about Corcept Therapeutics

All news →
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research · 1d ago▲ PositiveCan Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?Zacks Investment Research · Oct 19, 2026▲ PositiveThe Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme TherapeuticsZacks Investment Research · Oct 19, 2026▲ PositiveAre Options Traders Betting on a Big Move in Corcept Therapeutics Stock?Zacks Investment Research · Oct 13, 2026▲ PositiveCHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian CancerZacks Investment Research · Sep 21, 2026▲ Positive

Quick answers

What does Corcept Therapeutics do?
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome).
What is CORT's market cap?
$8.56B, based on the Nov 4 close of $79.22.
What is CORT's P/E ratio?
157.2× trailing-twelve-month earnings of $54.49M.
Does Corcept Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CORT is sold short?
8.6M shares, 9.0% of float, as of Oct 15, 2026.
What sector is CORT in?
Healthcare, in the Pharmaceuticals industry.

About Corcept Therapeutics

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

HQ: Redwood City, CA730 employeesListed Apr 14, 2004corcept.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology